Company Participation in Conferences - Verona Pharma's senior management will participate in the Jefferies Global Healthcare Conference on June 4, 2025, at 11:05 a.m. ET in New York, NY [1] - The company will also be present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 2:40 p.m. ET in Miami, FL [1] - Webcasts of each conference presentation will be available on the company's website [1] Company Overview - Verona Pharma is a biopharmaceutical company focused on developing therapies for chronic respiratory diseases with significant unmet medical needs [3] - The company's first commercial product, Ohtuvayre (ensifentrine), is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule [3] - Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases [3]

Verona Pharma plc (NASDAQ: VRNA ) is just three quarters into the launch of its chronic obstructive pulmonary disease (COPD) drug Ohtuvayre (ensifentrine), but the blockbuster drug discussion doesn't seem farfetched. When I last covered the nameScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disc ...

Verona Pharma (VRNA) Q1 2025 Earnings Call April 29, 2025 02:11 PM ET Speaker0 Welcome to Verona Pharma's First Quarter twenty twenty five Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen only mode. I'd now like to turn the call over to Victoria Stewart, Senior Director, Investor Relations and Communications. Please go ahead. Speaker1 Thank you. Earlier this morning, Corona Pharma issued a press release announcing its financial results for the three ...

Verona Pharma (VRNA) Q1 2025 Earnings Call April 29, 2025 09:00 AM ET Company Participants Victoria Stewart - Senior Director - Investor Relations & CommunicationsDavid Zaccardelli - President & CEOMark Hahn - Chief Financial OfficerAndrew Tsai - SVPChristopher Martin - Chief Commercial OfficerTiago Fauth - Director - Equity Research Small/Mid Cap BiotechnologyTara Rheault - Chief Development OfficerKathleen Rickard - Chief Medical OfficerRaghuram Selvaraju - Managing Director, Healthcare Equity Research Co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO __________ Commission File Number: 001-38067 Verona Pharma plc (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incor ...

Program Updates and Key Milestones Verona's near-term milestones include: Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 ® Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 – Verona Pharma plc (Nasdaq: ...

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quar ...

Company Overview - Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic respiratory diseases with significant unmet medical needs [3] - The company's first commercial product, OhtuvayreTM (ensifentrine), is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule [3] - Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases [3] Upcoming Financial Results - Verona Pharma will report its financial results for the first quarter ended March 31, 2025, on April 29, 2025 [1] - An investment community conference call will be hosted at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update [1] - A live webcast will be available on the company's website, and an audio replay will be accessible for 90 days [1]

Core Insights - The article emphasizes the importance of conducting independent research before making investment decisions, highlighting the inherent volatility and risks associated with stock investments [2][3]. Group 1 - The content is intended to provide informational insights rather than exhaustive analysis of any featured company [2]. - The predictions and opinions presented are based on a probabilistic approach, indicating that they do not guarantee absolute certainty [2]. - Readers are encouraged to verify the information independently and assess their financial circumstances before investing [2]. Group 2 - The article clarifies that past performance is not indicative of future results, underscoring the speculative nature of investments [3]. - It notes that the views expressed may not reflect those of the broader platform, indicating a diversity of opinions among analysts [3]. - The authors of the article include both professional and individual investors, some of whom may not be licensed or certified [3].

Core Viewpoint - Verona Pharma has successfully amended its strategic financing agreements, repaying the RIPSA and increasing its term loan facility to $450 million with improved terms, enhancing financial flexibility and simplifying its balance sheet [3][4]. Financing Agreements - The company repurchased the $100 million obligation under the RIPSA with reduced repayment fees [5]. - The term loan facility was increased to $450 million, with $125 million borrowed from an expanded Tranche C, resulting in an aggregate of $250 million outstanding [8]. - The interest rate on the term loan was reduced from 11% to 9.7%, with a further reduction to 9.35% upon achieving certain sales milestones [8]. - A provision was added allowing Verona Pharma to secure a working capital revolving credit facility of up to $75 million with a separate group [8]. Product Development - The ongoing success of the Ohtuvayre™ (ensifentrine) launch has been recognized, contributing to the growth of prescriptions and enabling the termination of the RIPSA [4]. - Ohtuvayre is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities [8]. - Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases [9]. Partnerships - Oaktree Capital Management and OMERS Life Sciences are key partners in the financing arrangements, expressing confidence in the US launch of Ohtuvayre and the company's growth prospects [4][10].